Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ahn, J. E.
Right arrow Articles by Leppik, I. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahn, J. E.
Right arrow Articles by Leppik, I. E.
Related Collections
Right arrow All Epilepsy/Seizures
NEUROLOGY 2008;71:38-43
© 2008 American Academy of Neurology

Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy

J. E. Ahn, PhD, J. C. Cloyd, PharmD, R. C. Brundage, PharmD, PhD, S. E. Marino, PhD, J. M. Conway, PharmD, R. E. Ramsay, MD, J. R. White, MD, L. C. Musib, PhD, J. O. Rarick, BS, A. K. Birnbaum, PhD and I. E. Leppik, MD

From the Department of Experimental and Clinical Pharmacology (J.E.A., J.C.C., R.C.B., S.E.M., J.M.C., L.C.M., J.O.R., A.K.B., I.E.L.), College of Pharmacy, and Department of Neurology (I.E.L.), University of Minnesota, Minneapolis; University of Miami (R.E.R.), FL; and MINCEP Epilepsy Care (J.R.W., I.E.L.), Minneapolis, MNA. is currently affiliated with ICON-US, Development Solutions, Ellicott City, MD. L.C.M. is currently affiliated with Eli Lilly and Company, Indianapolis, IN.

Address correspondence and reprint requests to Dr. James C. Cloyd, University of Minnesota, Rm 4-206, MTRF 2001 6th St, SE, Minneapolis, MN 55455 cloyd001{at}umn.edu

Background: Phenytoin (PHT) is widely used to treat epilepsy in elderly patients, but information on its pharmacokinetics in this population is limited.

Objective: The purpose of this study was to investigate the effects of age and sex on PHT pharmacokinetics using stable-labeled (SL) isotopes of PHT or fosphenytoin (FOS) administered IV or IM while patients remained on their oral maintenance regimen.

Methods: Subjects were patients 18 years or older with epilepsy, but otherwise healthy, on a maintenance regimen of PHT who were not taking interacting medications. Subjects were given a single injection of a 100 mg dose of SL-PHT or SL-FOS followed by their usual morning PHT dose less 100 mg. Serial blood samples were collected up to 196 hours after the SL dose. Plasma PHT and SL-PHT concentrations were measured by a gas chromatographic-mass spectrometric assay. PHT pharmacokinetics were characterized using a population-based, nonlinear, mixed-effects model.

Results: Sixty-three subjects completed the study, 45 of whom were 65 years or older. There was no difference between adult and elderly or men and women in PHT clearance, distribution volume, and elimination half-life. The mean elimination half-life was 40 hours.

Conclusions: Healthy elderly adults appear to have the same phenytoin (PHT) pharmacokinetics as younger adults. Reduced PHT dosage requirements may be due to age-related changes in patients' sensitivity to the therapeutic and toxic effects of the drug. The prolonged elimination half-life suggests that most patients can take PHT once daily and the time to reach steady-state may extend to 2–3 weeks.

Abbreviations: FOS = fosphenytoin; PHT = phenytoin; SL = stable-labeled.

Supplemental data at www.neurology.org

Supported by the following grants: NIH-NINDS P50 16308, NCRR M01-RR00400, NCRR M01-RR16587.

Disclosure: The authors report no disclosures.

Received August 15, 2007. Accepted in final form March 7, 2008.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.